Eterna Therapeutics Inc
$ 6.55
3.39%
11 Jun - close price
- Market Cap 7,394,600 USD
- Current Price $ 6.55
- High / Low $ 6.60 / 6.31
- Stock P/E 0.01
- Book Value 5.88
- EPS 1214.25
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.81 %
- ROE -25.06 %
- 52 Week High 66.25
- 52 Week Low 3.18
About
Brooklyn ImmunoTherapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat cancer patients. The company is headquartered in Brooklyn, New York.
Analyst Target Price
$30.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-11 | 2026-03-13 | 2025-11-07 | 2025-08-13 | 2025-05-07 | 2025-03-13 | 2024-11-12 | 2024-08-13 | 2024-05-13 | 2024-03-13 | 2023-11-13 | 2023-08-11 |
| Reported EPS | -6.95 | -4.8065 | -0.15 | -0.61 | -2.31 | -0.15 | -1844.085 | -383.8031 | -460.744 | -427.0564 | -1.0335 | -0.8516 |
| Estimated EPS | -1.95 | None | 0 | 0 | 0 | 0 | None | None | None | None | None | None |
| Surprise | -5 | 0 | -0.15 | -0.61 | -2.31 | -0.15 | 0 | 0 | 0 | 0 | 0 | 0 |
| Surprise Percentage | -256.4103% | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ERNA
2026-06-10 03:09:56
Ernexa Therapeutics discussed the significant unmet need in ovarian cancer and the potential of their ERNA-101 program during a Virtual Investor KOL Connect segment featuring Dr. Ira Winer. The discussion highlighted ERNA-101's dual mechanism, off-the-shelf scalability, and potential to address immunologically "cold" tumors, aiming to improve accessibility and affordability for patients. Ernexa Therapeutics is developing innovative cell therapies for advanced cancer and autoimmune diseases, with ERNA-101 specifically designed for ovarian cancer treatment.
2026-06-09 13:09:48
Ernexa Therapeutics, in a Virtual Investor KOL Connect segment featuring Dr. Ira Winer, discussed the significant unmet need in ovarian cancer and the potential of their ERNA-101 program. The discussion highlighted ERNA-101's dual mechanism, including tumor microenvironment remodeling and immune activation, and its advantages in manufacturing scalability and patient accessibility compared to personalized cell therapies. Dr. Winer emphasized the need for innovative approaches to overcome immunosuppressive tumor microenvironments and the potential for engineered cell therapies to convert "cold" tumors into responsive ones.
2026-06-09 08:41:00
Ernexa Therapeutics recently participated in a Virtual Investor KOL Connect segment, where Dr. Ira Winer discussed the significant unmet need in ovarian cancer and the challenges of treating immunologically "cold" tumors. The discussion highlighted Ernexa's ERNA-101 program and its potential advantages, including a dual mechanism approach for immune activation, scalable off-the-shelf manufacturing, and improved patient accessibility, using its engineered IL-7/IL-15 fusokine-iMSC platform. The company aims to provide new hope for patients with difficult-to-treat cancers through these innovative cell therapy strategies.
2026-06-03 09:39:45
This article provides recent news and events related to ERNA (Ernexa Therapeutics), including updates on its ovarian cancer treatment ERNA-101 and its planned IND submission. Key news highlights involve significant loss narrowing, positive therapy results, and a recent 1-for-25 reverse stock split. The company is actively progressing ERNA-101 development towards clinical study.
2026-05-28 09:10:39
Ernexa Therapeutics announced significant progress for its lead therapeutic candidate, ERNA-101, by completing manufacturing milestones including process development and transitioning to GMP manufacturing. These achievements position the company for a planned Investigational New Drug (IND) submission in Q3 2026, aiming to initiate its first-in-human clinical study. CEO Sanjeev Luther emphasized that these steps are critical for IND clearance and reflect the company's urgent and disciplined execution towards becoming a clinical-stage biotechnology company.
2026-05-28 04:39:34
This article provides access to the number of shareholders for Ernexa Therapeutics Inc. (NASDAQ: ERNA) through TradingView. It indicates that the specific shareholder data is available under the financials section for the pharmaceutical company. The content also briefly outlines various features and services offered by the TradingView platform.
